Skip to main content
ARROWHEAD PHARMACEUTICALS, INC. logo

ARROWHEAD PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · ARWR ISIN · US04280A1007 LEI · 549300O3CSB8T7OZ3D66 US Manufacturing
Open in API
Filings indexed 1,039 across all filing types
Latest filing 2016-09-29 Capital/Financing Update
Country US United States of America
Listing US ARWR

About ARROWHEAD PHARMACEUTICALS, INC.

https://arrowheadpharma.com/

Arrowhead Pharmaceuticals, Inc. is a biotechnology company that develops medicines to treat intractable diseases by silencing the genes that cause them. The company utilizes its proprietary RNA interference (RNAi) platform to create therapies that target disease pathways previously considered 'undruggable.' Arrowhead's development pipeline is focused on a broad range of therapeutic areas, including cardiometabolic, pulmonary, neuromuscular, and liver diseases. The company advances a portfolio of clinical-stage candidates designed to address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into material definitive agreements including collaboration and license agreements and a common stock purchase agreement with Amgen Inc. It also details the unregistered sale of equity securities related to these agreements. There are no financial statements or comprehensive financial data presented, nor is this an earnings release or annual/interim report. The document is primarily an announcement of a capital financing event and related agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive information about financing and agreements, so it is not a mere report publication announcement or regulatory filing fallback. Confidence is high due to clear identification of financing and capital structure changes.
2016-09-29 English
Regulatory Filings 2016
Regulatory Filings
2016-09-23 English
Regulatory Filings 2016
Regulatory Filings Classification · 100% confidence The document is a letter from Arrowhead Pharmaceuticals, Inc. to the SEC requesting acceleration of the effectiveness of a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and discusses procedural acknowledgments related to the filing's effectiveness. The document is short (2194 characters) and is a correspondence related to a regulatory filing, not the filing itself. It does not contain financial data or report content but is a procedural communication. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2016-09-20 English
Regulatory Filings 2016
Regulatory Filings
2016-09-19 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, which is a registration statement for securities offerings under the Securities Act of 1933. It includes detailed information about the securities being registered, the selling stockholders, risk factors, and other disclosures typical of a prospectus for a securities offering. This type of filing is related to capital raising activities and financing. It is not an annual report, earnings release, or any other type of financial or governance report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the actual registration statement and not just an announcement or notice.
2016-09-02 English
FORM 4/A SUBMISSION
Director's Dealing
2016-08-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.